NEWS
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
Atara Biotherapeutics has announced promising preclinical data for ATA3219, an allogeneic CD19-targeted CAR T therapy aimed at treating B-cell driven autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS). The data, to be presented at the ISCT 2024 Annual Meeting, show that ATA3219 effectively depletes CD19+ B-cells and induces lower levels of pro-inflammatory cytokines compared to autologous CD19 CAR T cells.
ATA3219 incorporates multiple clinically validated technologies, including a modified CD3ζ signaling domain and a less differentiated phenotype. A Phase 1 clinical trial for lupus nephritis (LN) and severe SLE without lymphodepletion is expected to begin in Q4 2024, with initial data anticipated in 2025.
ATA3219 incorporates multiple clinically validated technologies, including a modified CD3ζ signaling domain and a less differentiated phenotype. A Phase 1 clinical trial for lupus nephritis (LN) and severe SLE without lymphodepletion is expected to begin in Q4 2024, with initial data anticipated in 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1076Followers
68Following
7424Visitors
Follow